News and Announcements
Imugene Signs Three Existing Institutional Shareholders
- Published March 30, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Imugene Limited (ASX: IMU), an immune-oncology company is pleased to announce that is has signed underwriting agreements with three existing institutional shareholders of IMU to underwrite up to A$1.35 million of options as part of the Company’s option plan which expires on 31st March 2017.
KEY TAKEAWAYS:
- The agreed issue price for any shares issued under the underwriting agreements is 1.5 cents per share (being the same as the exercise price of the options) and the total underwriting fee is approximately 3.8% of the total underwritten amount (approx. $51,000).
- The underwriters are Platinum Investment Management Limited, Private Portfolio Managers and Celtic Capital, all existing and continued strong supporters of IMU over time.
IMU’s CEO, Leslie Chong said today “we are encouraged that such prominent shareholders have agreed to further increase their support and dedication by investing in Imugene. Funds raised from the options will be applied to continue our clinical development of HER-Vaxx and the pre-clinical work associated with the mimotope program.”
Imugene is an immuno-oncology focused biopharmaceutical company, developing HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric, ovarian, lung and pancreatic cancers.
Company Updates
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Asset over thematic: Centuria’s Andrew Essey warns against ‘blanket strategies’ as global capital eyes Australia
Relying solely on broad macroeconomic trends is the single biggest mistake property investors make today. Centuria Capital CIO Andrew Essey explains why asset-level “lettability” always trumps the overarching sector thematic, and reveals where global institutional capital is quietly pivoting to capture high-octane returns.
Material gains: Swinburne spin-out EntroMat takes aim at $160b global market
Traditional metallurgy has hit a performance wall. Discover how Swinburne University spin-out EntroMat is leveraging physics-based AI and circular critical minerals to engineer high-entropy alloys capable of surviving the world’s most extreme industrial environments.
Backed By Leading Investment Groups and Family Offices
